--- title: "Havas Health 和 BrightInsight 建立獨家聯盟，旨在解決製藥行業超過 5000 億美元的患者問題" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/277059428.md" description: "Havas Health 與 BrightInsight 建立了獨家合作伙伴關係，以解決製藥行業中患者依從性問題，這每年造成約 5000 億美元的損失。此次合作將 Havas Health 指定為 BrightInsight 的全球唯一代理合作伙伴，整合先進的數字健康解決方案，以增強患者在處方後的參與度。該合作旨在彌合治療處方與實際療效之間的差距，利用人工智能技術改善患者結果並降低治療中斷率。這一舉措反映了 Havas Health 對推動醫療溝通和技術發展的承諾" datetime: "2026-02-26T14:15:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/277059428.md) - [en](https://longbridge.com/en/news/277059428.md) - [zh-HK](https://longbridge.com/zh-HK/news/277059428.md) --- # Havas Health 和 BrightInsight 建立獨家聯盟，旨在解決製藥行業超過 5000 億美元的患者問題 , /PRNewswire/ - Havas Health today announced an exclusive, strategic partnership with BrightInsight, the leading global platform for biopharma to deliver digital persistence and adherence solutions. This collaboration designates Havas Health as BrightInsight's single global agency partner, creating a first-of-its-kind offering that merges world-class healthcare strategy and creativity with a compliant, scalable digital health platform to support and retain the patient post-prescription. The partnership addresses a critical friction point in the industry: the gap between a breakthrough therapy prescription and its ability to achieve real-world effectiveness. Built on an AI-enabled, compliant digital health platform, the collaboration reflects Havas Health's broader Converged strategy, fusing human insight with advanced technology to deliver integrated, scalable solutions across the healthcare journey. Havas Health excels at defining the patient journey to activate engagement, and BrightInsight brings the configurable, "always-on" technology which has demonstrated the ability to reduce long term therapy discontinuation by four percentage points and increase adherence by four percentage points more than traditional patient support programs. BrightInsight's compliant solution will drive tremendous incremental value for brands across the 60-plus countries Havas Health supports. "Our clients are no longer asking _if_ they should go digital, but how they can do so without reinventing the wheel for every market and every brand," said Jeff Hoffman, Chief Development Officer, Havas Health Network. "By integrating BrightInsight's platform into our core offering, Havas Health is moving beyond traditional communications. We are now providing our clients with a pre-vetted, regulatory-ready engine that ensures a patient's experience with a brand is as meaningful and reliable as the therapy itself. That's where long-term value and impact are truly realized." As treatment regimens become increasingly complex, and as more patients face chronic illnesses requiring lifelong management, patient adherence and persistence remain the primary barriers to clinical success. Industry analyses continue to estimate that poor patient adherence to prescribed therapies costs the global pharmaceutical industry approximately $500 billion annually.¹ This partnership allows Havas Health to rapidly deploy BrightInsight's solutions which have proven outcomes with top biopharma companies. These solutions bridge the value gap and deliver consistent clinical and commercial impact at scale. With a standardized but configurable digital health infrastructure, brands can both optimize and unify the support and experience provided to patients. "This partnership with Havas Health enables BrightInsight to bridge the gap between digital innovation and commercial scale," said Kal Patel, MD, CEO and Co-Founder of BrightInsight. "By aligning our platform with Havas' deep strategic influence and global reach, we can ensure that digital health solutions are successfully integrated into the brand's DNA and the patient's daily life, driving measurable impact for our partners and better outcomes for patients worldwide." This partnership represents the latest in a series of strategic alignments by Havas Health that underscore its commitment to advancing healthcare communications and technology. Building on collaborations with innovative platforms such as Ostro and Vurvey, Havas Health continues to invest in solutions that help clients build trust, demonstrate value, and scale confidently within an increasingly complex healthcare landscape. ¹ Source: Capgemini Consulting and HealthPrize Technologies; figure continues to be cited in industry reporting through 2025. **ABOUT HAVAS HEALTH NETWORK** Havas Health Network unites Havas Life, Havas Lynx, and Jacques, all wholly owned health and communications networks, with the consumer health businesses and practices of Havas Creative Network. The network's approach is centered around making a meaningful difference and has the talent, tenacity, and technology that health companies, brands, and people need to thrive in today's world. For more information, visit **www.HavasHealth.com**. **ABOUT BRIGHTINSIGHT** BrightInsight is the de facto global platform for biopharma patient persistence and adherence. As the only platform supporting regulated digital health across 60+ countries, BrightInsight is the trusted foundation for the world's largest biopharma brands. For life sciences companies pursuing digital transformation, the company offers the leading technology to rapidly develop, launch, and scale digital solutions. BrightInsight's cloud-based platform is the foundation for patient companion apps, digital-first patient support programs (PSP) and Software as a Medical Device (SaMD) solutions to improve medication persistence and adherence. For more details, visit BrightInsight's **website**, **Blog**, **X** and **LinkedIn** pages. View original content:https://www.prnewswire.com/news-releases/havas-health-and-brightinsight-forge-exclusive-alliance-to-tackle-pharmas-500b-patient-problem-302697564.html SOURCE Havas Health Network ### 相關股票 - [BBH.US](https://longbridge.com/zh-HK/quote/BBH.US.md) - [159316.CN](https://longbridge.com/zh-HK/quote/159316.CN.md) - [513060.CN](https://longbridge.com/zh-HK/quote/513060.CN.md) - [562050.CN](https://longbridge.com/zh-HK/quote/562050.CN.md) - [DRUG.US](https://longbridge.com/zh-HK/quote/DRUG.US.md) - [XBI.US](https://longbridge.com/zh-HK/quote/XBI.US.md) - [159849.CN](https://longbridge.com/zh-HK/quote/159849.CN.md) - [LABD.US](https://longbridge.com/zh-HK/quote/LABD.US.md) - [512290.CN](https://longbridge.com/zh-HK/quote/512290.CN.md) - [513700.CN](https://longbridge.com/zh-HK/quote/513700.CN.md) - [516500.CN](https://longbridge.com/zh-HK/quote/516500.CN.md) - [520500.CN](https://longbridge.com/zh-HK/quote/520500.CN.md) - [ARKG.US](https://longbridge.com/zh-HK/quote/ARKG.US.md) - [PBE.US](https://longbridge.com/zh-HK/quote/PBE.US.md) - [159506.CN](https://longbridge.com/zh-HK/quote/159506.CN.md) - [000863.CN](https://longbridge.com/zh-HK/quote/000863.CN.md) - [588130.CN](https://longbridge.com/zh-HK/quote/588130.CN.md) - [XLV.US](https://longbridge.com/zh-HK/quote/XLV.US.md) - [159837.CN](https://longbridge.com/zh-HK/quote/159837.CN.md) - [520880.CN](https://longbridge.com/zh-HK/quote/520880.CN.md) - [516930.CN](https://longbridge.com/zh-HK/quote/516930.CN.md) ## 相關資訊與研究 - [石四藥集團：美阿沙坦鉀已獲中國藥監局批准登記成為在上市製劑使用的原料藥](https://longbridge.com/zh-HK/news/287198604.md) - [核心醫療累虧超 4 億：產品單價下行，遞表前五次股權轉讓價劇烈波動](https://longbridge.com/zh-HK/news/286981242.md) - [鉅亨速報 - Factset 最新調查：Roivant Sciences LtdROIV-US 的目標價調升至 38 元，幅度約 8.57%](https://longbridge.com/zh-HK/news/287126179.md) - [川普投資組合神操作？Medicare 政策翻盤前 精準大買聯合健康](https://longbridge.com/zh-HK/news/287039034.md) - [石四藥 (2005):取得國家藥監局有關精氨酸培哚普利片 (5mg) 藥品生產註冊批件](https://longbridge.com/zh-HK/news/287189668.md)